Trileucine residues in a ligand-CPP-based siRNA delivery platform improve endosomal escape of siRNA (2017)
Sequence: YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRLLLLLc
| Experiment Id | EXP000364 |
|---|---|
| Paper | Trileucine residues in a ligand-CPP-based siRNA delivery platform improve endosomal escape of siRNA |
| Peptide | RVG9R5LC |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | very high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | Peptide:siRNA 20:1 |
| Rna Concentration | 100 pmol |
| Mixing Ratio | 20:1 molar ratio |
| Formulation Format | Peptide/siRNA complex |
| Formulation Components | Ligand-CPP peptide + siRNA |
| Size Nm | 147.00 |
| Zeta Mv | 22.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Neuro2a murine neuroblastoma cells |
| Animal Model | |
| Administration Route | |
| Output Type | Gene silencing; endosomal escape; uptake |
| Output Value | RVG9R3LC shows ~20–30% enhanced silencing at 24–48h |
| Output Units | |
| Output Notes | Trileucine improves endosomal escape; hemolysis and colocalization assays |
| Toxicity Notes | >4 Leu increases toxicity; ≤3 Leu non-toxic |
| Curation Notes |